NEW YORK/LONDON (Reuters) -U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping ...

Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.

Shares climbed as much as 3.5% in early European trade after Pfizer agreed to buy Metsera in a deal that could be worth more ...

Novo Nordisk lost an intense bidding war against Pfizer for U.S. biotech firm Metsera. CNBC takes a look at what the options ...

On November 4, 2025, just a day after Pfizer filed its suits against Novo Nordisk and Metsera, Novo Nordisk submitted an ...

Pharma giant had to pay a blockbuster price to buy Metsera after the biotech prospect spurred an auction with Novo Nordisk ...

Pfizer secures a $10B deal to buy Metsera, ending its fierce bidding war with Novo Nordisk and reigniting its push into the obesity market.

Pfizer wins Metsera after antitrust warning derails Novo's $9B bid; investors reward financial discipline over deal chasing.

Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, ...

Shares of Metsera fell over 15% in premarket trading on Monday, after the weight-loss drug developer accepted a sweetened ...

Get the daily news here. Read the essential Danish news and topics of today - in English. Politiken Edition is your window to ...

COPENHAGEN (Reuters) -Shares in Novo Nordisk rose on Monday after the Wegovy maker lost out to Pfizer in a $10 billion ...